Literature DB >> 2939433

[Osteocalcin (or bone gla-protein), a new biological marker for studying bone pathology].

P D Delmas, B Demiaux, L Malaval, M C Chapuy, P J Meunier.   

Abstract

Osteocalcin, also called bone gla-protein, is a bone matrix protein synthetized specifically by osteoblasts. It circulates in blood where it can be assayed by the radioimmune method. We measured osteocalcin serum levels in 169 adult controls and 161 patients with different disseminated or localized bone diseases. The normal concentration of 6.2 +/- 0.2 ng/ml increases significantly with age. Serum osteocalcin levels are considerably increased in renal osteodystrophy (114 +/- 23 ng/ml) and to a lesser degree in primary hyperparathyroidism (15.9 +/- 2.8 ng/ml) and Paget's disease (11.4 +/- 0.9 ng/ml), all diseases characterized by increased bone turnover. High levels are also encountered in osteomalacia (9.7 +/- 0.9 ng/ml). Conversely, serum osteocalcin levels are significantly decreased in patients under long-term corticosteroid therapy (4.3 +/- 0.5 ng/ml); they remain normal in patients with bone myeloma and bone metastases under treatment. Finally, osteocalcin is normal in patients with osteoporosis, but its level reflects that of bone turnover as evaluated by iliac bone biopsy. The circulating osteocalcin therefore is the first specific and sensitive marker for bone turnover. Serum osteocalcin measurements make it possible to evaluate the osteoblastic bone formation without biopsy and should provide information on the effectiveness of drugs acting on the bone-forming process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939433

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

1.  A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia.

Authors:  Ninib Baryawno; Dariusz Przybylski; Monika S Kowalczyk; Youmna Kfoury; Nicolas Severe; Karin Gustafsson; Konstantinos D Kokkaliaris; Francois Mercier; Marcin Tabaka; Matan Hofree; Danielle Dionne; Ani Papazian; Dongjun Lee; Orr Ashenberg; Ayshwarya Subramanian; Eeshit Dhaval Vaishnav; Orit Rozenblatt-Rosen; Aviv Regev; David T Scadden
Journal:  Cell       Date:  2019-05-23       Impact factor: 41.582

2.  Evaluation of mineral metabolism and bone turnover in osteoporotic females treated with phosphorus and salmon calcitonin.

Authors:  F P Cantatore; M Carrozzo; D M Magli; M D'Amore; V Pipitone
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

3.  Postoophorectomy bone loss is associated with reduced bone Gla protein serum levels: a possible effect of osteoblastic insufficiency.

Authors:  C E Fiore; E Falcidia; R Foti; S Caschetto; D R Grimaldi
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

4.  Self-assembling peptide nanofibers coupled with neuropeptide substance P for bone tissue engineering.

Authors:  Su Hee Kim; Woojune Hur; Ji Eun Kim; Hye Jeong Min; Sukwha Kim; Hye Sook Min; Byeung Kyu Kim; Soo Hyun Kim; Tae Hyun Choi; Youngmee Jung
Journal:  Tissue Eng Part A       Date:  2015-01-13       Impact factor: 3.845

5.  Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort.

Authors:  C Montecucco; F Baldi; A Fortina; G Tomassini; R Caporali; E L Cherie-Ligniere; P Fratino
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

6.  Risk of osteoporosis in men with chronic bronchitis.

Authors:  J P Praet; A Peretz; S Rozenberg; J P Famaey; P Bourdoux
Journal:  Osteoporos Int       Date:  1992-09       Impact factor: 4.507

7.  Type-I collagen produced by distinct fibroblast lineages reveals specific function during embryogenesis and Osteogenesis Imperfecta.

Authors:  Yang Chen; Sujuan Yang; Sara Lovisa; Catherine G Ambrose; Kathleen M McAndrews; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Commun       Date:  2021-12-10       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.